Evidence map›Paper›PMID 40736186›Full record

ReviewChinese medical journal2026

Applications and limitations of pluripotent stem cell-derived liver organoids.

Zhiwei Feng, Bingrui Zhou, Qizhi Shuai, Jianbing Mu, Jun Xie

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhiwei FengShanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Bingrui ZhouShanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Qizhi ShuaiShanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Jianbing MuLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, United States.
Jun XieShanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan, Shanxi 030001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractLiver disease is one of leading causes of death worldwide. However, current liver models have limited research progress. Therefore, models that accurately reflect the physiological functions of the human liver are urgently needed in both clinical and laboratory research. Over the past decade, liver organoids have emerged as valuable research tools offering significant breakthroughs and demonstrating great promise as advanced liver models. Liver organoids derived from pluripotent stem cells (PSCs), including embryonic and induced pluripotent stem cells, have shown significant potential for modeling liver diseases and drug responses. These miniature three-dimensional (3D) structures replicate the complexity of the liver and offer a platform for studying liver development and disease progression. The ability to create personalized organoids from patient-derived cells paves the way for precision medicine and drug screening. Owing to the pluripotency of PSCs, PSC-derived liver organoids (PSC-LOs) closely mimic the true structure of the liver and offer a wide range of applications. With advances in research, bioengineered liver organoids have the potential to revolutionize regenerative medicine, disease modeling, and the understanding of liver pathophysiology. This review provides an overview of liver organoid development and discusses their applications in liver regeneration, disease modeling, drug screening, toxicity assessment, organ transplantation, and regenerative medicine. Finally, we discuss the limitations and future development directions of PSC-LOs.

Indexed as

LiverOrganoidsPluripotent Stem CellsAnimalsHumansLiver DiseasesLiver RegenerationRegenerative MedicineApplicationGenerationLimitationLiver organoidsPluripotent stem cells

Identifiers

PMID40736186
PMCPMC12875692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.